论文部分内容阅读
目的:探讨MicroRNA-182在非小细胞肺癌中的表达及其临床意义。方法:采用RT-PCR检测30例Ⅰ-Ⅳ期非小细胞肺癌患者的癌及癌旁组织标本中MicroRNA-182表达水平差异,并分析其与患者临床参数之间关系。结果:MicroRNA-182在癌旁组织中相对表达量(23.35±23.10)明显高于癌组织中相对表达量(9.54±9.38),差异有统计学意义(P<0.05);MicroRNA-182表达水平与患者性别、年龄、肿瘤分期及大小、淋巴结转移、病理类型均无关联(P>0.05)。结论:MicroRNA-182基因与非小细胞肺癌发病关系密切,提示MicroRNA-182基因可作为非小细胞肺癌的诊断指标,与患者预后不相关。
Objective: To investigate the expression of MicroRNA-182 in non-small cell lung cancer and its clinical significance. Methods: The difference of MicroRNA-182 expression in cancer tissues and adjacent non-cancerous tissues from 30 patients with stage I-IV NSCLC was detected by RT-PCR. The relationship between them and the clinical parameters was analyzed. Results: The relative expression level of MicroRNA-182 in adjacent tissues (23.35 ± 23.10) was significantly higher than that in cancer tissues (9.54 ± 9.38), the difference was statistically significant (P <0.05) The gender, age, tumor stage and size, lymph node metastasis and pathological type had no correlation (P> 0.05). Conclusion: MicroRNA-182 gene is closely related to the pathogenesis of non-small cell lung cancer, suggesting that MicroRNA-182 gene can be used as a diagnostic marker for non-small cell lung cancer and has no correlation with prognosis.